Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Bacillus subtilis + Enterococcus faecium capsules after laparoscopic colorectal cancer surgery
ChiCTR2500096039Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Medilac-S in colorectal cancer (CRC) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: postoperative time to first flatus, time of first feeding after surgery and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Medilac-S
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500096039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096039.